Dr. Reddys Labs (RDY) Announces U.S. Launch of Generic Nitrostat Tabs
Get instant alerts when news breaks on your stocks. Claim your 2-week free trial to StreetInsider Premium here.
Dr. Reddy’s Laboratories Ltd (NYSE: RDY) announced that it has launched Nitroglycerin sublingual tablets USP, 0.3 mg, 0.4 mg and 0.6 mg, a therapeutic equivalent generic version of Nitrostat® (Nitroglycerin) sublingual tablets in the US market on August 26, 2016, having been approved by the United States Food & Drug Administration (USFDA).
The Nitrostat® (Nitroglycerin) sublingual tablet brand had U.S. sales of approximately $ 108 Million MAT for the most recent twelve months ending in March 2016 according to IMS Health*.
Dr. Reddy’s Nitroglycerin sublingual tablets USP, 0.4 mg is available in bottle count size of 100 and a bundle of 4 bottles of count size 25, Nitroglycerin sublingual tablets USP, 0.3mg is available in bottle count size of 100 and the Nitroglycerin sublingual tablets USP, 0.6mg is available in bottle count size of 100.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Wireless Telecom (WTT) Names Michael Kandell as CFO
- Fitbit (FIT) Announces Acquisition of Certain Pebble Assets
- Varian Medical Systems (VAR) Updates on Imaging Components Business Separation; Will Receive ~$200M
Create E-mail Alert Related CategoriesCorporate News, Management Comments
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!